EUCTR2015-002269-47-GB进行中（未招募）不适用
Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy. - SEL-I-METRY
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Diagnosed with locally advanced or metastatic differentiated thyroid cancer (papillary, follicular, Hürthle cell, or poorly differentiated carcinoma) with at least one measurable lesion as measured by computed tomography (CT) or magnetic resonance imaging (MRI)
- •Participants must have iodine refractory disease, defined below:
- •One or more measurable lesions that do not demonstrate iodine uptake on a previous radioiodine scan (diagnostic uptake or post therapy)
- •One or more measurable lesions that have progressed by RECIST 1.1 criteria within 12 months of I-131 therapy, despite demonstrable radioiodine avidity at the time of that treatment
- •Participants must have radiological progression by RECIST 1.1 criteria within the prior 12 months
- •Measurable disease by RECIST 1.1 criteria.
- •ECOG Performance Status = 1 and able to tolerate radioiodine therapy
- •Life expectancy of at least 12 weeks
- •Required laboratory values within 14 days of day 1 of treatment:
- •oAdequate thyroid-stimulating hormone (TSH) suppression < 0.5 mU/L
- •oCreatinine clearance >50 ml/min,
- •oAbsolute Neutrophil Count =1.5x109/L (1500 per mm3)
- •oPlatelets =100x109/L (100,000 per mm3)
- •oHaemoglobin >9.0 g/dL
- •oSerum bilirubin =1.5 x upper limit of normal (ULN)
- •oPatients with no liver metastasis must have AST or ALT = 2.5 x ULN
- •oPatients with liver metastasis must have AST or ALT = 5 x ULN. If patients have AST or ALT > 3.5 x ULN and = 5 x ULN they must have an ALP= 6 x ULN
- •Patient’s with Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of evidence of haemolysis or hepatic pathology) will be eligible.
- •Able to give informed consent and willing to follow trial protocol.
- •Aged over 18
- •Female participants of child-bearing potential must have a negative pregnancy test within 24 hours prior to starting therapy and agree to use dual methods of contraception for the duration of the trial and 6 months after completing treatment. Male participants must agree to use a barrier method of contraception for the duration of the trial and 4 months after completing treatment, if sexually active with a female of child-bearing potential.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •Foci of anaplastic thyroid cancer identified on histology
- •Able to receive curative surgery or radiation therapy
- •Major surgery with the exception of surgical placement for vascular access, open biopsy, or significant traumatic injury = 30 days prior to registration
- •Previous or concurrent cancer distinct in primary site or histology from thyroid cancer within previous 5 years, except for cervical cancer in situ, treated basal cell carcinoma, squamous cell carcinoma of the skin or superficial bladder tumour
- •Have received or are receiving an IMP or other systemic anticancer treatment within 4 weeks prior to the first dose of study treatment (6 weeks for nitrosoureas, mitomycin, and suramin), or within a period during which the IMP or anticancer treatment has not been cleared from the body (e.g. a period of 5 ‘half-lives’), whichever is the most appropriate and as judged by the investigator
- •Any unresolved toxicity =CTCAE Grade 2 from previous anti-cancer therapy, except for alopecia
- •Prior exposure to Tyrosine Kinase, MEK, RAS or RAF inhibitors
- •Known or suspected allergy to Selumentinib or hypersensitivity to Selumetinib or any excipient agents or history of allergic reactions attributed to compounds of similar chemical or biologic composition to Selumetinib
- •Known or suspected brain metastases or spinal cord compression, unless the condition has been asymptomatic, has been treated with surgery and / or radiation, and has been stable without requiring corticosteroids nor anti-convulsant medications for at least 4 weeks prior to the first dose of study medication
- •Requiring medication with high iodine content (e.g. amiodarone)
- •Participants who have had a iIodine contrast enhanced CT scan in previous 2 months
- •Ophthalmological conditions as follows:
- •oIntra-ocular pressure >21 mmHg, or uncontrolled glaucoma (irrespective of intra-ocular pressure)
- •oCurrent or past history of retinal pigment epithelial detachment (REPD)/central serous retinopathy or retinal vein occlusion
- •Any of the following cardiac conditions
- •oUncontrolled hypertension (BP =150/95 mmHg despite medical therapy)
- •oAcute coronary syndrome within 6 months prior to starting treatment
- •oUncontrolled angina (Canadian Cardiovascular Society grade II-IV despite medical therapy)
- •oSymptomatic heart failure (NYHA grade II-IV), prior or current cardiomyopathy, or severe valvular heart disease
- •oPrior or current cardiomyopathy including but not limited to the following:
- •?Known hypertrophic cardiomyopathy
- •?Known arrhythmogenic right ventricular cardiomyopathy
- •oSevere valvular heart disease
- •oLeft ventricular ejection fraction <55% measured by echocardiography
- •oAtrial fibrillation with a ventricular rate >100 bpm on ECG at rest
- •oQTcF >450ms or other factors that increase the risk of QT prolongation
- •Known to be infected with human immunodeficiency virus (HIV) or hepatitis B (HBV) or C (HCV) virus
- •Any evidence of severe or uncontrolled systemic disease(e.g. unstable or uncompensated respiratory, cardiac, hepatic, or renal disease),, active infection(including hepatitis B, hepatitis C, HIV), active bleeding diatheses or renal transplant
- •Pregnant or breastfeeding females
- •Male or female patients of reproductive potential who and, as judged by the investigator, are not employing an effective method of birth control
- •Have evidence of any other significant clinical disorder or laboratory finding that, as judged by the investigator, makes it undesirable for
研究者
相似试验
已完成
不适用
A clinical study for evaluating the efficacy of seasoning containing functional ingredients on the suppression of the elevation of postprandial serum triglyceride. (Randomised, placebo controlled crossover study)Healthy adultJPRN-UMIN000027767CPCC Company, Limited16
已完成
2 期
Clinical and Biochemical assessments of Passive Self-ligating Bracket System during Orthodontic treatmentTissue reaction to orthodontic force from two types of bracket systemspassive self-ligating bracket systemTCTR20180119002Faculty of Dentistry, Chiang Mai University13
已完成
不适用
What is the efficacy of therapist-guided and self-guided internet-delivered treatment for young adults (18-24) with symptoms of anxiety and depression?Mental Health - AnxietyMental Health - DepressionAnxietyDepressionACTRN12613000915752eCentreClinic, Centre for Emotional Health, Department of Psychology, Macquarie University300
招募中
不适用
Evaluation of clinical efficacy and safety of sentinel lymph node biopsy using magnetic nanoparticle and magnetic probeBreast cancerJPRN-UMIN000031240Japan Agency for Medical Research and Development180
尚未招募
2 期
Ayurvedic management of hyperactive childreCTRI/2022/07/044380Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital